Boston Scientific expands in niche

Article Excerpt

BOSTON SCIENTIFIC CORP., $100.31, is a buy. The company (New York symbol BSX; TSINetwork Rating: Average) (bostonscientific.com; Shares o/s: 1.5 billion; Market cap: $148.7 billion; No dividends paid) has agreed to acquire the rest of Bolt Medical for $443 million. The deal also includes payments of up to $221 million upon the achievement of certain regulatory milestones. Bolt is the developer of an intravascular-lithotripsy, or IVL, a laser-based platform for the treatment of coronary and peripheral artery disease. Intravascular-lithotripsy therapy represents one of the fastest-growing medical-device segments and addresses a significant but unmet need to treat patients with complex calcified arterial disease through a minimally invasive approach. Boston Scientific is still a buy. buy. …